T1	Participants 52 97	patients with pulmonary arterial hypertension
T2	Participants 172 223	patients with pulmonary arterial hypertension (PAH)
T3	Participants 505 581	patients with PAH to receive placebo or sitaxsentan 50 or 100Â mg once daily.
T4	Participants 895 963	98 randomized patients, 61% were WHO functional class II at baseline
